Provided by Tiger Trade Technology Pte. Ltd.

ALPHAMAB-B

7.485
-0.600-7.42%
Volume:1.88M
Turnover:14.39M
Market Cap:7.24B
PE:-62.38
High:8.055
Open:8.055
Low:7.480
Close:8.085
52wk High:15.750
52wk Low:6.230
Shares:967.00M
HK Float Shares:967.00M
Volume Ratio:2.34
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.120
ROE:-9.98%
ROA:-5.47%
PB:3.69
PE(LYR):-62.38
PS:11.93

Loading ...

BRIEF-Alphamab Oncology Says Phase III KN026-004 Study Enrolls 521 Patients And Meets Primary Endpoint

Reuters
·
Jun 01

Alphamab-B's KN026 Phase III Trial Data for HER2+ Breast Cancer Neoadjuvant Therapy Presented as Late-Breaking Oral at 2026 ASCO

Stock News
·
Jun 01

Alphamab Oncology - Phase Iii Kn026-004 Study Enrolls 521 Patients and Meets Primary Endpoint

THOMSON REUTERS
·
Jun 01

National Medical Insurance Catalog Adjustment Plan for 2026 Released; MOBVISTA (01860) Q1 Revenue Climbs 32.2%

Stock News
·
Jun 01

Alphamab secures NMPA clearance for bispecific antibody Anbenitamab in second-line HER2-positive gastric cancer

Bulletin Express
·
May 29

ALPHAMAB-B (09966) Announces NMPA Approval for Ennituo® (Anituo Monoclonal Antibody Injection)

Stock News
·
May 29

Alphamab Oncology - Anbenitamab Injection (Kn026) Obtains Marketing Approval From Nmpa in China

THOMSON REUTERS
·
May 29

3D Medicines says Phase III data for Envafolimab plus GEMOX in advanced biliary tract cancer to be presented at 2026 ASCO meeting

Reuters
·
May 27

ALPHAMAB-B Shares Surge as Key Research Findings Selected for Prestigious 2026 ASCO Conference

Stock News
·
May 26

Assessing Alphamab Oncology’s Valuation After JSKN033 Phase II Trial Progress In Advanced Cervical Cancer

Simply Wall St.
·
May 26

ALPHAMAB-B Shares Surge Over 5% on Milestone Enrollment Completion for Envafolimab's New Indication Phase III Trial

Stock News
·
May 22

Alphamab Oncology Expands Share Capital by 0.009 % Through Option Exercise

Bulletin Express
·
May 21

ALPHAMAB-B Issues Shares Following Option Exercise

Stock News
·
May 21

Alphamab Oncology Outlines 12 June 2026 AGM Agenda, Seeks Fresh Share Issuance and Repurchase Mandates

Bulletin Express
·
May 20

Alphamab Oncology Sets 12 June 2026 AGM; Seeks 10% Buy-back and 20% Issuance Mandates, Plans Director Re-elections and Auditor Renewal

Bulletin Express
·
May 20

Alphamab Oncology announces annual general meeting

Reuters
·
May 20

Biotech Stocks Plunge Amid Global Bond Selloff and Rising Interest Rate Concerns

Stock News
·
May 18

Alphamab Oncology Doses First Patient in Phase 2 Study of JSKN033

MT Newswires Live
·
May 13

ALPHAMAB-B (09966) Announces First Patient Dosed in Phase II Study for JSKN033 in First-Line Advanced Cervical Cancer

Stock News
·
May 13

Alphamab Oncology doses first patient in Phase II JSKN033 cervical cancer trial

Reuters
·
May 13